Details of the Drug Combination

General Information of Drug Combination (ID: DCDMDVS)

Drug Combination Name
Rifabutin GS-9620
Indication
Disease Entry Status REF
Human Immunodeficiency Virus Type 1 (HIV-1) Infection Phase 1 [1]
Component Drugs Rifabutin   DM1YBHK GS-9620   DMG5C8D
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL is unavailable 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Rifabutin
Disease Entry ICD 11 Status REF
Mycobacterium infection 1B10-1B21 Approved [2]
Tuberculosis 1B10-1B14 Approved [2]
Rifabutin Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
DNA-directed RNA polymerase (RNAP) TTHKJLN NOUNIPROTAC Modulator [5]
------------------------------------------------------------------------------------
Rifabutin Interacts with 1 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [6]
------------------------------------------------------------------------------------
Indication(s) of GS-9620
Disease Entry ICD 11 Status REF
Hepatitis B virus infection 1E51.0 Phase 2 [3]
Human immunodeficiency virus infection 1C62 Phase 1 [4]
GS-9620 Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Toll-like receptor 7 (TLR7) TTRJ1K4 TLR7_HUMAN Modulator [3]
------------------------------------------------------------------------------------
GS-9620 Interacts with 1 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [7]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT05458102) Drug-Drug Interaction Study of Vesatolimod in Adults With HIV-1 Who Have Very Low or Undetectable Virus Levels
2 Novel agents in the management of Mycobacterium tuberculosis disease. Curr Med Chem. 2007;14(18):2000-8.
3 Pharmacokinetic and pharmacodynamic properties of GS-9620, a novel Toll-like receptor 7 agonist, demonstrate interferon-stimulated gene induction without detectable serum interferon at low oral doses. J Pharmacol Exp Ther. 2014 Jan;348(1):96-105.
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
6 The effect of multiple doses of ritonavir on the pharmacokinetics of rifabutin. Clin Pharmacol Ther. 1998 Apr;63(4):414-21.
7 The oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection. J Hepatol. 2015 Aug;63(2):320-8.